Immuron (ASX:IMC) reported global sales for its immune supplement, Travelan, of roughly AU$2.5 million in the December 2024 quarter, a surge of 249% year on year, according to a Friday filing with the Australian bourse.
Sales in Australia soared 315% to nearly AU$1.9 million, while North American sales climbed 141% to AU$652,000.
Global half-year sales jumped 70% to AU$4 million.
The biopharmaceutical company's shares climbed past 8% in recent Friday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。